Veracity Capital LLC Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Veracity Capital LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,614 shares of the biopharmaceutical company’s stock after selling 58 shares during the period. Regeneron Pharmaceuticals makes up approximately 1.4% of Veracity Capital LLC’s investment portfolio, making the stock its 9th largest holding. Veracity Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $3,999,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. Avior Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 29.1% in the 4th quarter. Avior Wealth Management LLC now owns 1,190 shares of the biopharmaceutical company’s stock worth $848,000 after acquiring an additional 268 shares during the period. Traynor Capital Management Inc. boosted its stake in Regeneron Pharmaceuticals by 10.7% during the 4th quarter. Traynor Capital Management Inc. now owns 24,790 shares of the biopharmaceutical company’s stock valued at $17,659,000 after purchasing an additional 2,400 shares in the last quarter. Hudson Capital Management LLC increased its position in shares of Regeneron Pharmaceuticals by 7.8% during the 4th quarter. Hudson Capital Management LLC now owns 4,961 shares of the biopharmaceutical company’s stock valued at $3,534,000 after purchasing an additional 357 shares during the period. Janney Montgomery Scott LLC raised its stake in shares of Regeneron Pharmaceuticals by 21.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,066 shares of the biopharmaceutical company’s stock worth $16,431,000 after buying an additional 4,130 shares in the last quarter. Finally, BDF Gestion acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $1,956,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on REGN shares. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Bank of America restated an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Finally, Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $694.64 on Friday. The stock has a market capitalization of $76.33 billion, a P/E ratio of 17.19, a P/E/G ratio of 1.59 and a beta of 0.10. The business has a 50-day moving average of $730.57 and a two-hundred day moving average of $942.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.